Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI128 vs febuxostat in gout with hyperuricemia (Phase III, China)
CTR20260560Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tigulixostat in gout, hyperuricemia, sponsored by InnoCare Pharma. Started Mar 2026; status: active.
02
Drugs
tigulixostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20260560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260560.